CHICAGO--(BUSINESS WIRE)--The University of Massachusetts Medical School (UMMS) and Lundbeck Inc. today announced a research collaboration aimed at further development of a targeted therapy to slow or halt the progression of Huntington’s disease (HD). At this time, there is no way to stop or reverse the course of HD, a challenging hereditary neurodegenerative disease characterized by a triad of progressive motor, cognitive and emotional symptoms.1 This collaboration will support a distinguished group of scientists in the study of RNAi-based therapies as a possible method for selectively suppressing production of mutant huntingtin (mHtt), the abnormal protein that causes HD.2
